- 期刊
- OpenAccess
Safety of Ablative Radioiodine Therapy for Differentiated Thyroid Cancer in a Patient with End-Stage Renal Disease under Hemodialysis
並列摘要
Ablative radioiodine therapy is the main standard treatment for patients with differentiated thyroid cancer after total thyroidectomy. After radioiodine therapy, more than 70% of the radioiodine is excreted in urine. In patients with end-stage renal disease (ESRD) and anuria, the biological half-life of radioiodine increases and patients might accumulate more of the radiation dose. Radioiodine is removed by hemodialysis in patients with ESRD. However, there have been not many studies on radiation safety and removal of radiation activity in patients with ESRD. A 49-year-old female patient with ESRD who received 70 mCi 131I was the subject of investigation and a 24-year-old female patient with normal renal function was recruited as the control for comparison. A portable dosimeter was placed on the anterior chest wall to detect radiation changes at 4-hour intervals. After 3 days of hospital isolation, the patients were discharged. The patient with ESRD received a hemodialysis session on the day she was discharged and the radiation dose was checked every hour. During hospitalization, the immediate radiation dose in the patient with ESRD decreased much more slowly than that in the patient with normal renal function. Hemodialysis decreased the estimated radiation dose accumulation by about 60%.
參考文獻
被引用紀錄
延伸閱讀
- 郭仕勳、顏亨軒、呂姿瑩、黃旼儀、張寶樹、黃鈺婷、王鈞彥（2019）。Retrospective Evaluation on Dosimetric Comparison and Thyroid Cancer Risks for Three Treatment Planning System on Nasopharyngeal Carcinoma Irradiation。臺灣醫事放射期刊，7(1)，17-26。https://doi.org/10.6717/JTMRT.201906_7(1).0003
- Rentziou, G., Saltiki, K., Manios, E., Stamatelopoulos, K., Koroboki, E., Vemmou, A., Mantzou, E., Zakopoulos, N., & Alevizaki, M. (2014). Effects of Recombinant Human Thyrotropin Administration on 24-Hour Arterial Pressure in Female Undergoing Evaluation for Differentiated Thyroid Cancer. International Journal of Endocrinology, 2014(), 380-387-040. https://doi.org/10.1155/2014/270213
- Chen, C. Y., Liu, W. S., Chung, M. J., Yang, S. H., Chang, P. J., & Lin, D. B. (2005). Radioiodine Therapy for Well-Differential Thyroid Cancer: Internal Dosimetric Evaluation for Thyroidectomy Patient. 中山醫學雜誌, 16(2), 335-344. https://doi.org/10.30096/CSMJ.200512.0014
- Cheng, R. C., Lin, K. J., Lee, G. Y., Wang, S. F., Ju, L. R., & Kuo, S. F. (2015). Radioiodine Clearance and Quality of Life in Thyroid Cancer Patients with Radioiodine Ablation: A Comparison between Thyroid Hormone Withdrawal and Recombinant Human Thyroid Stimulating Hormone Injection. 核子醫學暨分子影像雜誌, 28(1), 3-9. https://doi.org/10.6332/ANMMI.2801.001
- Zagar, I., Pevec, A. A. S., Kralj, B. V., Horvat, R., & Besic, N. (2012). Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma. Journal of Thyroid Research, 2012(), 221-231. https://doi.org/10.1155/2012/670180